Even people which have never smoked can develop lung cancer. In this population a mutation in the exons 19-21 of the Epidermal Growth Factor Receptor (EGFR) can be detected. For this patient group targeted therapies with EGFR tyrosinkinase inhibitors are available. In this case report we describe a 37 year old non-smoker who developed a non-small cell lung cancer. Following therapy with Erlotinib a partial response could be achieved.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00108-008-2239-0 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!